Eisai Obtains Additional Approval for Its Thrombolytic Agent Cleactor Inj.Tokyo, Japan, Aug 5, 2005 - (JCNN JCNN Japan Corporate News Network ) - Eisai has received approval for an additional indication of its thrombolytic agent thrombolytic agent Clot-dissolving drug, thrombolytic An agent–eg, tPA, streptokinase, that effects thrombolysis and restores vascular patency–eg, in managing acute MIs. See Thrombolytic therapy, tPA. , Cleactor Inj. (monteplase), from the Ministry of Health, Labor and Welfare. Cleactor Inj. is now available in the treatment of acute pulmonary embolism Pulmonary Embolism Definition Pulmonary embolism is an obstruction of a blood vessel in the lungs, usually due to a blood clot, which blocks a coronary artery. with hemodynamic instability. Currently, the company offers three dosage forms: Cleactor Inj. 400,000, Cleactor Inj. 800,000 and Cleactor Inj. 1,600,000. Eisai expects that the new indication will contribute to the field of critical care. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion